Fate Therapeutics Inc. [NASDAQ: FATE] gained 37.80% or 22.98 points to close at $83.77 with a heavy trading volume of 6425007 shares. The company report on December 6, 2020 that Fate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma.
Off-the-Shelf, iPSC-derived CAR NK Cell Product Candidate Drives Partial Response at First Dose Level of 30 Million Cells.
Deepening of Response Observed with FT596 Retreatment.
It opened the trading session at $68.483, the shares rose to $89.92 and dropped to $68.165, the range by which the price of stock traded the whole day. The daily chart for FATE points out that the company has recorded 156.02% gains over the past six months. However, it is still -531.75% lower than its most recent low trading price.
If we look at the average trading volume of 911.69K shares, FATE reached to a volume of 6425007 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Fate Therapeutics Inc. [FATE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FATE shares is $53.31 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FATE stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Fate Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 13, 2020. While these analysts kept the previous recommendation, Barclays raised their target price to Overweight. The new note on the price target was released on March 04, 2020, representing the official price target for Fate Therapeutics Inc. stock. Previously, the target price had yet another raise to $22, while BMO Capital Markets analysts kept a Market Perform rating on FATE stock. On December 30, 2019, analysts increased their price target for FATE shares from 27 to 33.
The Average True Range (ATR) for Fate Therapeutics Inc. is set at 4.78, with the Price to Sales ratio for FATE stock in the period of the last 12 months amounting to 396.92. The Price to Book ratio for the last quarter was 17.17, with the Price to Cash per share for the same quarter was set at 5.64.
Trading performance analysis for FATE stock
Fate Therapeutics Inc. [FATE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 43.28. With this latest performance, FATE shares gained by 67.81% in over the last four-week period, additionally plugging by 156.02% over the last 6 months – not to mention a rise of 512.80% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FATE stock in for the last two-week period is set at 88.75, with the RSI for the last a single of trading hit 94.14, and the three-weeks RSI is set at 84.41 for Fate Therapeutics Inc. [FATE]. The present Moving Average for the last 50 days of trading for this stock 49.78, while it was recorded at 65.15 for the last single week of trading, and 35.68 for the last 200 days.
Fate Therapeutics Inc. [FATE]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Fate Therapeutics Inc. [FATE] shares currently have an operating margin of -943.14. Fate Therapeutics Inc.’s Net Margin is presently recorded at -919.00.
Return on Total Capital for FATE is now -45.06, given the latest momentum, and Return on Invested Capital for the company is -44.32. Return on Equity for this stock declined to -48.44, with Return on Assets sitting at -38.09. When it comes to the capital structure of this company, Fate Therapeutics Inc. [FATE] has a Total Debt to Total Equity ratio set at 11.00. Additionally, FATE Total Debt to Total Capital is recorded at 9.91, with Total Debt to Total Assets ending up at 8.91. Long-Term Debt to Equity for the company is recorded at 10.31, with the Long-Term Debt to Total Capital now at 9.29.
Reflecting on the efficiency of the workforce at the company, Fate Therapeutics Inc. [FATE] managed to generate an average of -$551,399 per employee. Receivables Turnover for the company is 42.72 with a Total Asset Turnover recorded at a value of 0.04.Fate Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.20 and a Current Ratio set at 9.20.
Fate Therapeutics Inc. [FATE]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Fate Therapeutics Inc. posted -0.37/share EPS, while the average EPS was predicted by analysts to be reported at -0.39/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 5.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FATE.
An analysis of insider ownership at Fate Therapeutics Inc. [FATE]
There are presently around $7,283 million, in the hands of institutional investors. The top three institutional holders of FATE stocks are: REDMILE GROUP, LLC with ownership of 12,629,737, which is approximately 0% of the company’s market cap and around 0.90% of the total institutional ownership; FMR LLC, holding 6,971,568 shares of the stock with an approximate value of $584.01 million in FATE stocks shares; and BLACKROCK INC., currently with $550.09 million in FATE stock with ownership of nearly 7.647% of the company’s market capitalization.
Positions in Fate Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 117 institutional holders increased their position in Fate Therapeutics Inc. [NASDAQ:FATE] by around 7,131,885 shares. Additionally, 84 investors decreased positions by around 6,054,520 shares, while 28 investors held positions by with 73,748,989 shares. The mentioned changes placed institutional holdings at 86,935,394 shares, according to the latest SEC report filing. FATE stock had 30 new institutional investments in for a total of 727,769 shares, while 19 institutional investors sold positions of 1,122,906 shares during the same period.